Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
Duality Biotherapeutics
Watchlist
Pre-IPO Duality Biotherapeutics - Has the Potential to Surpass RemeGen
Equity Capital Markets
534 Views
26 Dec 2024 00:55
Founder Zhu Zhongyuan's role in biotech landscape helped Duality secure a high starting point, but slower R&D progress is a concern.Potential for higher valuation exists due to promising pipeline
What is covered in the Full Insight:
Introduction
R&D Progress and Market Competition
Partnerships and Collaborations
Core Products and Market Challenges
Valuation and Future Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »
Loading
Trending Collections
More »
South Korea
Japan
India
Index Rebalance
Unpaywalled Insights
Event-Driven
Equity Bottom-Up
Sell / Short Ideas
Philippines
Asia Event-Driven
Trending Insights
More »
Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
StubWorld: Melco (200 HK) Needs To Fall
EB Event Trade Setup: HD KSOE Lining up a New Deal with HD Hyundai Heavy as the Underlying
Japan Activist Watch | Square Enix, DaitoTrust, Iriso & INES
Lotte Corp Sells 145 Billion Won Worth of Treasury Shares to Lotte Moolsan - Negative Governance
Top Unpaywalled Insights
More »
"The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
[IO Technicals 2025/25] Bearish Momentum Strengthens
VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Pre-IPO FWD Group Holdings (PHIP Updates) - The Pain Points and the Outlook
24 Jun 2025
Pre-IPO GenFleet Therapeutics - The Pipeline Outlook Is Full of Challenges
27 May 2025
Pre-IPO Duality Biotherapeutics (PHIP Updates) - Some Points Worth the Attention
25 Mar 2025
Shanghai Henlius Biotech (2696.HK) - Privatization Has Taken a Positive Step Forward
26 Aug 2024
Pre-IPO Tong Ren Tang Healthcare Investment - Profitability and Growth Sustainability Are Worrying
21 Aug 2024
Pre-IPO Medtide - The Industry, the Business and the Concerns
20 Aug 2024
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.6
x